Q2 2026 saw 24% adjusted EBITA growth (6% organic), 18% net sales growth, and a 10% EBITA margin. Strong cash flow, robust M&A pipeline, and stable segment performance were reported, with leverage at 2.37x and RONWC at 69%.Based on Asker Healthcare Group AB [ASKER] Q2 2026 Audio Transcript — Jul. 2…
Q2 2026 saw 24% adjusted EBITA growth (6% organic), 18% net sales growth, and a 10% EBITA margin. Strong cash flow, robust M&A pipeline, and stable segment performance were reported, with leverage at 2.37x and RONWC at 69%.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.